BioSpace Movers & Shakers: Singular Genomics, Marengo, Ventyx, Caribou and more
Building stronger businesses requires good leadership. This week, life science companies around the world are identifying the Movers & Shakers that will best benefit their business.
Singular genomics: Based in California, Singular Genomics Systems, Inc. formed its scientific council. New members include Singular Genomics Board Member David L. Barker, as well as AmideBio and Aspen Neuroscience; Lawrence Fong, professor of cancer biology at the University of California, San Francisco; David H. Ledbetter, clinical and research director at the United Patient Network; Elaine Mardis, board member and co-executive director of the Institute of Genomic Medicine at Nationwide Children’s Hospital; and Daniel Shoemaker, former scientific director of Fate Therapeutics.
Marengo therapy: Ke Liu was named Director of Development and Bruce Chabner was named Senior Strategic Advisor. Liu recently served as SVP at Sana Biotechnology. Previously, he spent more than 17 years working for the United States Food and Drug Administration with significant leadership responsibilities, including Chief of the Oncology Branch in the Office of Tissue and Advanced Therapies at the Center for Biologics Evaluation and Research (CBER), and the Associate Director for Cell and Gene Therapy at the FDA Oncology Center of Excellence. Chabner is a professor of medicine at Harvard Medical School. He has extensive experience and was a key research pioneer in cancer drug discovery and development. During his career at the National Cancer Institute, he served as Principal Investigator in the Chemical Pharmacology Laboratory, Head of the Clinical Pharmacology Branch, Director of the Clinical Oncology Program, and Director of the Cancer Treatment Division.
Oncorus, Inc.: Richard Wanstal was appointed chief financial officer of Oncurus, based in Cambridge, Massachusetts. Most recently, he served as Chief Financial Officer and Treasurer of Aileron Therapeutics. Prior to Aileron, Wanstall served as vice president of finance at Moderna Therapeutics and senior vice president of finance at Stream Global Services. Previously, Wanstall was vice president of finance at Art Technology Group, vice president at Taxware and chief financial officer at CNET.
DNA script: Chris Barbazette was appointed commercial director. Barbazette joins DNA Script from Resolve Biosciences, where he served as CCO and established the US headquarters for the German parent company. Prior to Resolve, Barbazette held management and executive positions at several life sciences and diagnostics companies, including Genapsys and Agendia.
Fluidic Sphere: Evelyn Stevenson and Ravi Girdhar join British company Sphere as Director of Product Management and Director of Sales, respectively. Stevenson has worked with companies such as Azenta Life Sciences, Lonza and Thermo Fisher Scientific. Girdhar has held various commercial positions with GE Healthcare, Thermo Fisher Scientific and Gyros Protein Technologies. Additionally, Denise Emsden has been named Vice President of People and Organizational Development. Emsden has significant experience in various industries, including life sciences, such as Abcam, Mundipharma and Elite Sports Juddmonte.
To evolve: Kaile Zagger has been named Managing Director of Evolve. She began her career in the Global Leadership Development Program at General Electric and earned the coveted Black Belt in Six Sigma. She has been recognized as one of the “Top Ten COOs of 2021”, received a coveted spot as “Top World Leader in Healthcare” in 2022 and is repeatedly recognized as a cutting-edge leader in the FemTech space. from year to year.
Quantum-Si Incorporated: patrick schneider was named President and Chief Operating Officer. Schneider joins Quantum-Si from MilliporeSigma, where he most recently served as senior vice president of strategy, business development and innovation and chairman of the Life Science Innovation Board. Earlier in his career, Schneider served as Vice President of R&D, Business Development and Scientific Affairs at Serologicals, Inc. He was also CSO at Chemicon International, where he founded the Beckman Institute for biomedical research and co-founded Genome Biosciences, Inc. and Integrated Cell Technologies, Inc.
BioAgilytix Laboratories: Lynn Kamen and Michelle Miller have been appointed Chief Scientists of BioAgilytix. Kamen worked at Genentech as a Principal Scientist within the Developmental Sciences organization, leading the bioanalytical analysis of large molecules from late-stage research through to the clinic. Miller worked with BioAgilytix previously as associate bioanalytical director. Prior to joining the company, she led GLP toxicology and immunotoxicology studies and developed high throughput screening assays as a principal investigator. She has also worked as an R&D scientist in the pharmaceutical industry. David King has also been appointed to the company’s board of directors. King is the former Executive Chairman and CEO of Laboratory Corporation of America Holdings (Labcorp). King currently sits on several professional boards, including Privia Health, ZimVie and VaxCare. Her volunteer board involvement includes Novant Health, PATH, and the Emily Krzyzewski Center.
Clearmind Medicine: Christian G. Schütz and Mark Weiser have been appointed to Clearmind’s Scientific Advisory Board. Schütz is associate professor of psychiatry at the University of British Columbia and Weiser is chair of the department of psychiatry at the Sackler School of Medicine.
BrainsWay Ltd. : Eric Hurt has been named vice president of US sales. Hirt previously led Aerogen’s US sales team. Prior to Aerogen, he held senior sales positions at Teleflex and Integra LifeSciences and senior sales and marketing positions at Covidien (now part of Medtronic).
LUMICKS: André Nel has been appointed Chief Financial Officer. Nel most recently served as Chief Financial Officer of Dante Labs, a global leader in consumer genome sequencing testing services. Previously, he spent nearly seven years at Illumina, ending as vice president of finance. In more than eight years at Pfizer, he served as Chief Financial Officer of the Russian Federation, Center of Excellence for Global Transformation and European Business Intelligence, Head of Finance, and Head of Financial Planning and Reporting.
General Science: Genenta, based in Italy, has appointed Tim Obara as vice president of business development. He joins Genenta from the University of Pennsylvania’s gene therapy program, where he was executive director of research operations. He previously held senior roles in business development at Amicus Therapeutics, AstraZeneca, GSK and Singapore-based Tessa Therapeutics.
Loyalty: Israel-based Fairtility has named Cristina Hickman vice president of clinical affairs. Hickman served as Chief Embryologist at Boston Place Clinic, where she developed the world’s first IVF clinic designed around time-lapse technology.
Genetic Opus: jennifer chase was appointed director of development. Prior to joining Opus, she held key clinical and regulatory positions at several biopharmaceutical companies, including Genzyme, Voyager Therapeutics and Editas Medicine. At Editas, she oversaw the development of CRISPR drugs in ophthalmology, hemoglobinopathies and oncology.
Organic Xequel: Jerry St. Peter was named CEO and Wes Brazell was named chief financial officer. Jerry St. Peter brings more than 30 years of executive leadership specializing in biopharmaceuticals implementing strategic planning, business operations, financial management, fundraising, business development and overall general management. Prior to joining Xequel, St. Peter was CEO and President of Eyevance Pharmaceuticals. He was also co-founder, CEO and board member of Eyevance Pharmaceuticals prior to its acquisition by Santen. Prior to co-founding Eyevance, St. Peter led Sun Pharmaceuticals’ new Ophthalmic division. Brazell was chief financial officer for Eyevance and, prior to that, was chief financial officer of TearLab. Brazell spent 21 years in several financial management roles at Alcon, including Vice President Finance for Alcon’s U.S. operations, Vice President Finance for Alcon’s operations in Europe, the Middle East and in Africa and Vice President of Corporate Financial Planning and Analysis.
Ventyx Biosciences: William Sandborn was named President and CMO. Sandborn was co-founder and CMO at Shoreline Biosciences. Previously, he was co-founder of Santarus. Sandborn was a professor of medicine and head of the division of gastroenterology at the University of California, San Diego.
Caribou Biosciences: David L. Johnson has been appointed to the board of directors of Caribou Biosciences, Inc. Johnson is currently Chief Commercial Officer of Global Blood Therapeutics. Previously, Johnson spent 15 years at Gilead Sciences, Inc., where he held positions of increasing responsibility in the company’s sales organization.
Phavaris: The Swiss company Pharvaris named Joan Schmidt to the newly created position of Chief Legal Officer. Schmidt most recently served as general counsel and secretary at Arena Pharmaceuticals. Prior to Arena, Schmidt served as general counsel at DBV Technologies and general counsel in the United States and head of human resources at Biotronik. Previously, Schmidt held positions of increasing responsibility at Novo Nordisk, both in the United States and in Europe.
Therapeutic Elicio: Peter DeMuth has been named CSO and Joy Semour has been named Head of Regulatory Affairs. Seymour was most recently the global head of cell therapy regulation at Bristol-Myers Squibb. DeMuth has evolved into a multi-faceted role at Elicio from his early days as a scientist on the bench to becoming CSO. Prior to joining Elicio, DeMuth worked extensively with company co-founder Dr. Darrell Irvine at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.